Лучевые повреждения мочевого пузыря при раке предстательной железы: обзор литературы

   Введение. Радиационные повреждения мочевого пузыря – одно из наиболее распространенных осложнений лучевой терапии злокачественных новообразований малого таза.

   Материалы и методы. Проведены поиск, анализ и систематизация релевантных публикаций в базах данных e.Library.ru, cyberleninka.ru, PubMed. Отобрано 65 статей, которые включены в настоящий обзор.

   Результаты и обсуждение. Приведены данные об эпидемиологии, факторах риска, патогенезе, профилактике, диагностике и лечении лучевых повреждений мочевого пузыря.

   Выводы. Гипербарическая оксигенация, внутрипузырные инстилляции глюкозоаминогликановой кислоты и хондроитина сульфата, а также трансуретральная фульгурация остаются наиболее эффективными методами лечения лучевых повреждений мочевого пузыря.

1. Рак предстательной железы. Клинические рекомендации Министерства здравоохранения РФ. URL: https://cr.minzdrav.gov.ru/preview-cr/12_3 (дата обращения: 20. 12. 2024).

2. NCCN guidelines version 1.2025. Prostate cancer. Available from: www.nccn.org/patients. Cited 2020 Dec 20.

3. EAU guidelines. Prostate cancer. Available from: https://uroweb.org/guidelines/prostate-cancer.

4. Lee V, An Y, Park HS. et al. Emergency department visits for radiation cystitis among patients with a prostate cancer history. BJU Int. 2022; 130 (2): 208–216. doi: 10.1111/bju.15650

5. Crew JP, Jephcott CR, Reynard JM. Radiation-induced haemorrhagic cystitis. Eur Urol. 2001; 40 (2): 111–23. doi: 10.1159/000049760

6. Halperin E. C., Perez С. А., Brady L. W. Perez and Brady’s principles and practice of radiation oncology. 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2008. 2106 p.

7. Denton AS, Clarke NW, Maher EJ. Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database of Systematic Reviews. 2002; 3: IDCD 001773.

8. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31 (5): 1341–6. doi: 10.1016/0360–3016(95)00060-C

9. Fuentes-Raspall R, Inoriza JM, Rosello-Serrano A. et al. Late rectal and bladder toxicity following radiation therapy for prostate cancer: predictive factors and treatment results. Rep Pract Oncol Radiother. 2013; 18 (5): 298–303. doi: 10.1016/j.rpor.2013.05.006

10. Detti B, Baki M, Becherini C, Saieva C. et al. High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experience. Radiol Med. 2019; 124 (5): 422–431. doi: 10.1007/s11547-018-0977-1

11. Anderson J.F., Swanson D.A., Levy L.B. et al. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology. 2009; 74 (3): 601–5. doi: 10.1016/j.urology.2009.04.060

12. Hebert KJ, Matta R, Fendereski K. et al. Genitourinary radiation injury following prostate cancer treatment: assessment of cost and health care system burden. Urology. 2023; 179: 166–173. doi: 10.1016/j.urology.2023.03.056

13. Бердичевский В. Б., Гутрова Е. И., Налетов А. А. и др. Радионуклидиндуцированный цистит. Современный взгляд на проблему. Академический журнал Западной Сибири. 2020; 16 (5 (88)): 45–47.

14. Bologna E, Licari LC, Franco A. et al. Incidence and management of radiation cystitis after pelvic radiotherapy for prostate cancer: analysis from a national database. Urology. 2024; 191: 86–92. doi: 10.1016/j.urology.2024.04.035

15. Lonergan PE, Baskin A, Greenberg SA. et al. The Long-term incidence and quality of life outcomes associated with treatment-related toxicities of external beam radiotherapy for prostate cancer. Urology. 2023; 178: 114–119. doi: 10.1016/j.urology.2023.05.012

16. Sanguedolce F, Sancho Pardo G. et al. Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies. Prostate Int. 2021; 9 (1): 48–53. doi: 10.1016/j.prnil.2020.07.006

17. Afonso-João D, Pacheco-Figueiredo L, Antunes-Lopes T. et al. Cumulative incidence and predictive factors of radiation cystitis in patients with localized prostate cancer. Actas Urol Esp (Engl Ed). 2018; 42 (4): 256–261. doi: 10.1016/j.acuro.2017.06.009

18. Makino K, Sato Y, Takenaka R. et al. Cumulative incidence and clinical risk factors of radiation cystitis after radiotherapy for prostate cancer. Urol Int. 2023; 107 (5): 440–446. doi: 10.1159/000521723

19. Doiron RC, Witten J, Rourke KF. The scope, presentation, and management of genitourinary complications in patients presenting with high-grade urethral complications after radiotherapy for prostate cancer. Can Urol Assoc J. 2021; 15 (1): E 6–E 10. doi: 10.5489/cuaj.6599

20. David RV, Islam A, Miller J. et al. Genitourinary toxicity after pelvic radiation : prospective review of complex urological presentations. Asian J Urol. 2024; 11 (4): 633–641. doi: 10.1016/j.ajur.2023.01.006

21. Gatsinga R, Lim BJH, Kumar N. et al. Radiation-induced hemorrhagic cystitis in prostate cancer survivors: the hidden toll. Medicina (Kaunas). 2024; 60 (11): 1746. doi: 10.3390/medicina60111746

22. Li X, Shan L, Wang Q. et al. Comparison of chronic gastrointestinal and genito-urinary toxicities between brachytherapy and external beam radiotherapy for patients with prostate cancer : a systematic review and meta-analysis. Technol Health Care. 2023; 31 (S 1): 357–372. doi: 10.3233/THC-236031

23. Tward JD, Jarosek S, Chu H. et al. Time course and accumulated risk of severe urinary adverse events after high- versus low-dose-rate prostate brachytherapy with or without external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2016; 95 (5): 1443–1453. doi: 10.1016/j.ijrobp.2016.03.047

24. Gill S, Thomas J, Fox C. et al. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol. 2011; 6: 145. doi: 10.1186/1748-717X-6-145

25. Сафронова Е. В. Оценка степени острой местной токсичности при лечении рака предстательной железы радикальным методом лучевой терапии с модуляцией интенсивности дозы при разных режимах фракционирования. Онкологический журнал. 2016; 10 (1 (37)): 55–58.

26. Baskin A, Cowan JE, Braun A, et al. Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer. Urol Oncol. 2023; 41(10): 429.e9–429.e14. doi: 10.1016/j.urolonc.2023.06.003

27. Киреева Т. А., Гуменецкая Ю. В., Бирюков В. А. и др. Оценка токсичности лечения при профилактическом облучении лимфатических узлов малого таза у больных раком предстательной железы высокого риска прогрессирования. Онкология. Журнал им. П. А. Герцена. 2022; 11 (2): 20–24. doi: 10.17116/onkolog20221102120

28. Sutani S, Ohashi T, Sakayori M. et al. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy. Radiother Oncol. 2015; 117 (2): 270–6. doi: 10.1016/j.radonc.2015.08.019

29. Inokuchi H, Mizowaki T, Norihisa Y. et al. Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: a 10-year follow-up study of genitourinary toxicity in clinical practice. Clin Transl Radiat Oncol. 2017; 6: 31–36. doi: 10.1016/j.ctro.2017.09.005

30. Shinde A, Li R, Han C, Frankel P. et al. Dosimetric predictors of genitourinary toxicity from a phase i trial of prostate bed stereotactic body radiation therapy. Pract Radiat Oncol. 2021; 11 (1): e90–e97. doi: 10.1016/j.prro.2020.06.004.

31. Сидорова С. А., Школьник М. И., Богомолов О. А. и др. Частота лучевых повреждений у больных раком предстательной железы, получивших комбинированное гормонолучевое лечение после закрытия эпицистостомы. Ученые записки СПбГМУ ИМ. акад. И. П. Павлова. 2015; XXII (03): 51–53.

32. Massi MC, Gasperoni F, Ieva F. et al. A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE multi-national cohort. Front Oncol. 2020; 10: 541281. doi: 10.3389/fonc.2020.541281

33. Шуленина Л. В., Михайлов В. Ф., Раева Н. Ф. и др. МикроРНК в крови пациентов с раком предстательной железы как возможный показатель ранних осложнений лучевой терапии. Радиационная биология. Радиоэкология. 2017; 57 (6): 598–607.

34. Корытов О. В., Корытова Л. И., Григорьев С. Г. Исследование рисков возникновения лучевых реакций у пациентов, получающих облучение органов малого таза. Российский биотерапевтический журнал. 2024; 23 (2): 69–77. doi: 10.17650/1726-9784-2024-23-2-69-77

35. Neckonoff E, Anderson CB. Advancements in understanding and managing radiation cystitis : a comprehensive review. Curr Urol Rep. 2024; 26 (1): 1. doi: 10.1007/s11934-024-01238-0

36. Chargari C, Supiot S, Hennequin C. et al. Treatment of radiation-induced late effects: what’s new? Cancer Radiother. 2020; 24 (6–7): 602–611. doi: 10.1016/j.canrad.2020.06.007.S1278-3218(20)30177-3

37. Boström M, Kalm M, Eriksson Y. et al. A role for endothelial cells in radiation-induced inflammation. Int J Radiat Biol. 2018; 94 (3): 259–271. doi: 10.1080/09553002.2018.1431699

38. Venkatesulu B., Mahadevan L., Aliru M. Radiation-induced endothelial vascular injury : a review of possible mechanisms. JACC Basic Trans Science. 2018; 3 (4): 563–572. doi: 10.1016/j.jacbts.2018.01.014

39. Стрельцова О. С., Моисеев А. А., Киселева Е. Б. и др. Оперативная прижизненная оценка состояния соединительной ткани мочевого пузыря в возможности прогнозирования тяжести лучевого поражения. Экспериментальная и клиническая урология. 2018; (4): 40–45.

40. Бердичевский В. Б., Гутрова Е. И., Хилькевич С. В. и др. Клинико-морфологические особенности проявления хронического бактериального, лучевого и БЦЖ-индуцированного цистита. Медицинский вестник Башкортостана. 2022; 17 (4 (100)): 22–25.

41. Helissey C, Cavallero S, Mondot S. et al. Correlation between serum and urine biomarkers and the intensity of acute radiation cystitis in patients treated with radiation therapy for localized prostate cancer: Protocol for the Radiotoxicity Bladder Biomarkers (RABBIO) study. JMIR Res Protoc. 2023; 12: e38362. doi: 10.2196/38362

42. Meziani L, Deutsch E, Mondini M. Macrophages in radiation injury: a new therapeutic target. OncoImmunology. 2018; 7 (10): e1494488. doi: 10.1080/2162402x.2018.1494488

43. Foro P, Algara M, Lozano J. et al. Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study. Int J Radiat Oncol Biol Phys. 2014; 88 (5): 1057–1063. doi: 10.1016/j.ijrobp.2014.01.002.S0360-3016(14)00005-4

44. Zwaans BMM, Nicolai HE, Chancellor MB. et al. Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine. PLoS One. 2020; 15 (10): e0241388. doi: 10.1371/journal.pone.0241388

45. Zwaans BMM, Bartolone SN, Chancellor MB. et al. Altered angiogenic growth factors in urine of prostate cancer survivors with radiation history and radiation cystitis. Urology. 2018; 120: 180–186. doi: 10.1016/j.urology.2018.07.025

46. Lojanapiwat B, Sripralakrit S, Soonthornphan S, et al. Intravesicle formalin instillation with a modified technique for controlling haemorrhage secondary to radiation cystitis. Asian J Surg. 2002; 25 (3): 232–5. doi: 10.1016/S1015-9584(09)60181-0

47. Терехов О. В., Пасов В. В. Лечение поздних лучевых повреждений мочевого пузыря. Эффективная фармакотерапия. 2014; (32): 26–31.

48. Redorta JP, Sanguedolce F, Pardo GS. et al. Multicentre International Study for the Prevention with iAluRil of Radio-induced Cystitis (MISTIC): a randomised controlled study. Eur Urol Open Sci. 2021; 26: 45–54. doi: 10.1016/j.euros.2021.01.016

49. Gacci M, Saleh O, Giannessi C. et al. Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study. BMC Urol. 2015; 15: 65. doi: 10.1186/s12894-015-0046-1

50. Кульченко Н. Г. Медикаментозное лечение осложнений после лучевой терапии. Исследования и практика в медицине. 2018; 5 (S 1): 52.

51. Каприн А. Д., Титова В. А., Иванов С. А. и др. Системная и внутрипузырная озонотерапия при циститах после радикальной лучевой терапии и комплексного лечения злокачественных опухолей малого таза. Онкоурология. 2006; (4): 35–37.

52. Hamilton K, Bennett NC, Purdie G. et al. Standardized cranberry capsules for radiation cystitis in prostate cancer patients in New Zealand: a randomized double blinded, placebo-controlled pilot study. Support Care Cancer. 2015; 23(1): 95–102. doi: 10.1007/s00520-014-2335-8

53. Herst PM, Aumata A, Sword V. et al. Cranberry capsules are not superior to placebo capsules in managing acute non-haemorrhagic radiation cystitis in prostate cancer patients: a phase III double blinded randomised placebo controlled clinical trial. Radiother Oncol. 2020; 149: 117–123. doi: 10.1016/j.radonc.2020.05.006

54. Лоран О. Б., Синякова Л. А., Митрохин А. А. и др. Гипербарическая оксигенация в лечении поздних постлучевых циститов. Экспериментальная и клиническая урология. 2010; (2): 73–77.

55. Lin ZC, Bennett MH, Hawkins GC. et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2023 15; 8 (8): CD 005005. doi: 10.1002/14651858.CD005005.pub5

56. Sarrió-Sanz P, Sanchez-Caballero L, Martinez-Cayuelas L. et al. Efficacy, tolerance and predictors of response to the treatment with hyperbaric oxygen therapy for patients with hemorrhagic radiation cystitis. Arch Esp Urol. 2022; 75 (4): 354–360. doi: 10.56434/j.arch.esp.urol.20227504.50

57. Dellis A, Papatsoris A, Kalentzos V. et al. Hyberbaric oxygen as sole treatment for severe radiation – induced haemorrhagic cystitis. Int Braz J Urol. 2017; 43 (3): 489–495. doi: 10.1590/S1677-5538.IBJU.2016.0451

58. Gaio-Lima C, Castedo J, Cruz M. et al. The role of hyperbaric oxygen therapy in the treatment of radiation lesions. Clin Transl Oncol. 2022; 24 (12): 2466–2474. doi: 10.1007/s12094-022-02892-x

59. Cardinal J, Slade A, McFarland M. et al. Scoping review and meta-analysis of hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. Curr Urol Rep. 2018; 19 (6): 38. doi: 10.1007/s11934-018-0790-3

60. Oscarsson N, Müller B, Rosén A. et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. Lancet Oncol. 2019; 20 (11): 1602–1614. doi: 10.1016/S1470-2045(19)30494-2

61. Ravi R. Endoscopic neodymium: YAG laser treatment of radiation-induced hemorrhagic cystitis. Lasers Surg Med. 1994; 14 (1): 83–7. doi: 10.1002/lsm.1900140116.

62. Talab SS, McDougal WS, Wu CL. et al. Mucosa-sparing, KTP laser coagulation of submucosal telangiectatic vessels in patients with radiation-induced cystitis: a novel approach. Urology. 2014; 84 (2): 478–83. doi: 10.1016/j.urology.2014.03.029

63. Zhu J, Xue B, Shan Y. et al. Transurethral coagulation for radiation-induced hemorrhagic cystitis using Greenlight™ potassium-titanyl-phosphate laser. Photomed Laser Surg. 2013; 31 (2): 78–81. doi: 10.1089/pho.2012.3396

64. Martinez DR, Ercole CE, Lopez JG. et al. A novel approach for the treatment of radiation-induced hemorrhagic cystitis with the GreenLightTM XPS Laser. Int Braz J Urol. 2015; 41 (3): 584–7. doi: 10.1590/S1677–5538

65. Principles and Practice of Radiation Oncology (seventh edition) / eds. E. C. Halperin, D. E. Wazer, C. A. Perez, L. W. Brady. Wolters Kluwer, Philadelphia; 2019. Chapter 69–70. P. 1560–1622.